news
EC approves Avastin plus Tarceva in NSCLC
8 June 2016 | By Victoria White, Digital Content Producer
The combination is approved for the first-line treatment of adult patients with non-squamous NSCLC with EGFR-activating mutations...
List view / Grid view
European Commission (EC)
news
EC approval for Afinitor for the treatment of neuroendocrine tumours
2 June 2016 | By Victoria White, Digital Content Producer
The EC has approved Afinitor (everolimus) for the treatment of neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease...
news
EC approves Trevicta for the treatment of schizophrenia
1 June 2016 | By Victoria White, Digital Content Producer
The EC has approved the use of Trevicta (paliperidone palmitate a 3-monthly injection) for the maintenance treatment of schizophrenia in adult patients...
news
EC approves MabThera for chronic lymphocytic leukaemia
The EC has approved the subcutaneous formulation of MabThera for people with previously untreated and relapsed/refractory chronic lymphocytic leukaemia...
news
EC approves ibrutinib for patients with newly diagnosed CLL
31 May 2016 | By Victoria White, Digital Content Producer
The European Commission (EC) has approved Imbruvica (ibrutinib) for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).
news
EC approves Empliciti as combination therapy for multiple myeloma
12 May 2016 | By Victoria White, Digital Content Producer
Empliciti (elotuzumab) is approved for use with Revlimid (lenalidomide) and dexamethasone in patients who have received at least one prior therapy...
news
EC approves Opdivo + Yervoy regimen for advanced melanoma
11 May 2016 | By Victoria White, Digital Content Producer
The approval of Opdivo + Yervoy represents the first and only approved combination of two Immuno-Oncology agents in the European Union (EU)...
news
EC approves eribulin for the treatment of advanced liposarcoma
5 May 2016 | By Victoria White, Digital Content Producer
Eribulin is approved for those patients who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease...
news
EC grants orphan designation to pSivida’s Medidur
3 May 2016 | By Victoria White, Digital Content Producer
The EC has granted orphan medicinal product designation to Medidur for the treatment of chronic non-infectious uveitis of the posterior of the eye...
news
EC grants marketing authorisation to Lonsurf in mCRC
27 April 2016 | By Victoria White, Digital Content Producer
The decision from the EC was based on data from the international, double-blind, placebo-controlled Phase III RECOURSE study...
news
EC grants marketing authorisation to Lilly’s ixekizumab
26 April 2016 | By Victoria White, Digital Content Producer
The EC has granted marketing authorisation for Lilly’s ixekizumab (Taltz) for the treatment of moderate-to-severe plaque psoriasis in adults...
news
EC grants marketing authorisation for two doses of Gilead’s Descovy
25 April 2016 | By Victoria White, Digital Content Producer
Descovy is the first new HIV backbone approved in Europe in more than a decade and represents an important advance in addressing the needs of patients...
news
EC approves Opdivo in NSCLC and advanced kidney cancer
14 April 2016 | By Victoria White, Digital Content Producer
The EC has granted approval for the use of Opdivo (nivolumab) to treat patients with the most common forms of advanced lung and advanced kidney cancer...
news
EC grants marketing authorisation to afatinib in SqCC of the lung
7 April 2016 | By Victoria White, Digital Content Producer
Afatinib is approved for the treatment of patients whose disease has progressed on or after treatment with platinum-based chemotherapy...
news
EU approval for Revolade for paediatric patients with chronic ITP
7 April 2016 | By Victoria White
The approval includes the use of a new oral suspension formulation of Revolade designed for younger children who may not be able to swallow tablets...
